Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 10-11, 2020. Onconova Therapeutics, Inc. (ONTX) stock forum ... NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced that the Company will release its year-end 2019 financial results on Tuesday, March 24, 2020, after the market closes.